Melanoma-associated antigen 12 (MAGE-A12) peptide-MHC complex (MAGE-A12)

Melanoma-associated antigen 12 (MAGE-A12) is a member of the MAGE-A family of cancer-testis antigens, which are typically expressed only in the germ cells of the testis and placenta (UniProt: P43366). Since these tissues do not express MHC Class I molecules, MAGE-A12 is not normally presented to the immune system. However, MAGE-A12 is frequently overexpressed in various malignancies, including melanoma and lung cancer, where its processed peptides are presented on the cell surface by MHC molecules (PubMed: 23857983). This tumor-specific presentation makes the MAGE-A12 peptide-MHC complex a target for T-cell receptor (TCR) engineered T-cell therapies. Clinical trials have demonstrated that targeting this antigen can induce significant tumor regression; however, they also revealed critical safety concerns. Specifically, low-level expression of MAGE-A12 in the human brain, particularly the hypothalamus, led to severe and fatal necrotizing leukoencephalopathy in patients treated with cross-reactive TCRs (PubMed: 23857983, PubMed: 28234734). Consequently, while MAGE-A12 remains a potent target for immunotherapy, its clinical application requires rigorous screening for off-tumor reactivity.

Other names

MAGEA12Cancer/testis antigen 1.12CT1.12Melanoma antigen family A 12

T-cell receptor-mediated recognition of the peptide-MHC complex leading to cytotoxic T-lymphocyte activation and tumor cell lysis.